ArticleCancer medicine2025
Breast Cancer Detection Patterns in Year 2 of the COVID-19 Pandemic Highlight Gains and Gaps in Breast Cancer Surveillance.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe COVID-19 pandemic severely hindered breast cancer (BC) diagnoses. We investigated the impact of COVID-19 on BC diagnoses in the US.
methodsWe retrospectively reviewed the 2024 release of the Surveillance, Epidemiology, and End Results database (SEER: 2000-2021) for invasive BC incidences per 100,000 in adult women. Using the SEER Joinpoint software, we modeled BC incidence trends through 2019 and extrapolated expected incidences in 2020-2021. We compared expected and observed incidences and calculated percent differences (PD) and the national deficit in diagnoses.
resultsObserved BC incidence in 2020 was 122.03, while expected incidence was 132.14, yielding a PD of -7.6% [-8.9%, -6.4%]. In 2021, observed BC incidence exceeded projections (3.5% [2.1%, 4.8%]). These translated to a cumulative deficit of 7190 cases [-11,886, -2494] during 2020-2021. Localized and regional BC detection decreased in 2020 and was within (1.4% [-0.9%, 3.7%]) or exceeded (4.1% [4.2%, 4.4%]) projections, respectively, in 2021. Distant disease detection was within projections in 2020 and exceeded projections in 2021 (3.9% [0.6%, 7.2%]). Across most demographic subgroups, detection was low in 2020. In 2021, cases exceeded projections in White women and metropolitan and high education/income counties, were within projections in racial/ethnic minorities and rural and low education/income counties, and were below projections in 85+ year olds and 10%-19.99% foreign-born counties.
conclusionsBC detection recovered in 2021 compared to the start of the pandemic, but notable disparities persisted. Careful surveillance and study are needed to prevent further gaps in BC detection years after the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.